August 19, 2016 6:16am

… Investors are hesitatant to put their money to work as trading dominates the sector’s market

Also, there isn't any sector-moving news and who wants to be long over a summer weekend

 

… Companies in my headlights: AGTC, CLLS, JUNO, KITE, PSTI and STEM

 

I answer one question; in which company should investors put, keep and commit their money!

 

Where is today’s market going? 

Subscribe and find out! 

 

 

Where do investors turn for insight and perspective - I say what others won't, so you can do what others can't!

 

 

Indexes and ETFs: The IBB (+0.01%), XBI (+0.10) and IWM (+0.01) are UP while the XLV (-0.01%) is DOWN

Dow futures are DOWN -0.24% and NASDAQ futures are DOWN -0.29%

 

U.S. stock index futures indicated a lower open on Friday morning as traders eyed the latest rig count data for more signs that U.S. production could pick up with rising crude prices

European stocks traded lower as investors paused for breath as oil prices came off their highs while the debate over a U.S. interest rate rise among policymakers raged on.

Asia markets gave up early modest gains, with the Japanese market slipping after the yen strengthened briefly during the session.

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) sector closed POSITIVE on Thursday, NEGATIVE on Wednesday and Tuesday, POSITIVE on Monday and last Friday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

  • Thursday closed POSITIVE with 14 decliners,  26 advancers and 3 flats;
  • Wednesday closed NEGATIVE with 33 decliners, 9 advancers and 1 flat;
  • Tuesday closed NEGATIVE with 28 decliners, 12 advancers and 3 flats;
  • Monday closed POSITIVE with 13 decliners, 28 advancers and 2 flats;
  • Last Friday closed POSITIVE with 14 decliners, 27 advancers and 2 flats;

 

 

Remembering Thursday’s closing post, “Stem, cell, gene and regenerative therapy stocks on Thursday flipped between small gains and losses.  Bias will persist to the downside and below support zones, however … Even after pullbacks that breach support; there could be lower resistance where investors could expect significant buying.”

  • Stem, cell, gene and regenerative therapy stocks ended higher Thursday, boosted by being oversold after a run-down post a run-up that helped classify the timing of historical and noticed patterns.

I won’t be extending any new insight into new near and long- term exposure. I say be patient and more than a bit cautious.

  • Don’t forget that we’re heading into the end of summer and the Labor Day holiday weekend.

I’d hold on most equities and stick my head in the sand until after Labor Day!

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed Thursday up +0.26% and is UP +0.01% in Friday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Thursday up +0.40% and is UP +0.10% in Friday’s  pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed up Thursday +0.04% and is DOWN -0.01% in Friday’s pre-market;
  • The iShares Russell 2000 (IWM) closed up +0.75% on Thursday and is UP +0.01% in Friday’s pre-market.

 

 

Companies in my headlights:

Applied Genetic Technologies (AGTC) closed DOWN -$0.30 to $14.83. Oversold, as reflected by the 20 closes in the $15.00+ range since July; 6 closes at $14.00+ and 1 close at $16.00+ in 27 sessions partially justifies my prognostication. Even though financial results/earnings haven’t been announced, the Biogen (BIIB) investment is amortized over successive Qs - BUY;

Cellectis SA (CLLS) closed DOWN -$0.43 to $26.71 after Wednesday’s $27.14 (-$0.73). CLLS is oversold as reflected the past five day’s pricings of Tuesday’s $27.87, Monday’s $28.23 and last Friday’s $27.59. The aftermarket indication is positive +$0.21 – Maintaining BUY;

Juno Therapeutics (JUNO) closed UP +$0.18 to $34.02. The week has been whimsical post earnings re Wednesday’s $33.84, Tuesday’s $34.21, Monday’s $32.92 and last Friday’s $32.66. The aftermarket indication is negative -$0.42. Let the market speak – SELL;

Kite Pharma (KITE) closed UP +$0.03 to $60.35. The week has seen weakness re Wednesday’s $60.32, Tuesday’s $61.84, Monday’s $62.51 and last Friday’s $60.16. The aftermarket indication is positive +$0.65 - BUY

Pluristem (PSTI) closed UP +$0.06 to $1.74 after Wednesday’s $1.68 (+$0.02) following Tuesday’s $1.66 (+$0.07), Monday’s $1.59 and last Friday’s $1.54. PSTI has experienced some new highs that usually don’t last. It’s about investor perception and it “ain’t” positive … Maintaining SELL;

StemCells (STEM) closed DOWN -$0.18 to $1.66 after Wednesday’s $1.84 (-$0.76) after Tuesday’s $2.60 (+$2.2278 or +598.55%) post the announcement of a merger agreement. The run-up was TOO extreme making it a target for profit taking initiatives as day traders were the major influence in its past pricing. The aftermarket indication is negative -$0.02 – Maintaining SELL;

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.